Lo Emily Kwun Kwan, Xu Jing-Hang, Zhan Qiao, Zeng Zheng, El-Nezami Hani
School of Biological Sciences, University of Hong Kong, Pokfulam, Hong Kong 999077, China.
Department of Infectious Diseases, Peking University First Hospital, Peking University, Beijing 100034, China.
Biomedicines. 2022 Jun 18;10(6):1444. doi: 10.3390/biomedicines10061444.
Chronic liver diseases pose a substantial health burden worldwide, with approximately two million deaths each year. Branched-chain amino acids (BCAAs)-valine, leucine, and isoleucine-are a group of essential amino acids that are essential for human health. Despite the necessity of a dietary intake of BCAA, emerging data indicate the undeniable correlation between elevated circulating BCAA levels and chronic liver diseases, including non-alcoholic fatty liver diseases (NAFLD), cirrhosis, and hepatocellular carcinoma (HCC). Moreover, circulatory BCAAs were positively associated with a higher cholesterol level, liver fat content, and insulin resistance (IR). However, BCAA supplementation was found to provide positive outcomes in cirrhosis and HCC patients. This review will attempt to address the contradictory claims found in the literature, with a special focus on BCAAs' distribution, key signaling pathways, and the modulation of gut microbiota. This should provide a better understanding of BCAAs' possible contribution to liver health.
慢性肝病在全球范围内构成了沉重的健康负担,每年约有200万人死亡。支链氨基酸(BCAAs)——缬氨酸、亮氨酸和异亮氨酸——是一组对人体健康至关重要的必需氨基酸。尽管饮食中摄入BCAAs是必要的,但新出现的数据表明,循环中BCAAs水平升高与慢性肝病之间存在不可否认的关联,包括非酒精性脂肪性肝病(NAFLD)、肝硬化和肝细胞癌(HCC)。此外,循环中的BCAAs与较高的胆固醇水平、肝脏脂肪含量和胰岛素抵抗(IR)呈正相关。然而,研究发现补充BCAAs对肝硬化和HCC患者有积极效果。本综述将试图解决文献中发现的相互矛盾的观点,特别关注BCAAs的分布、关键信号通路以及肠道微生物群的调节。这将有助于更好地理解BCAAs对肝脏健康可能的贡献。